EUVIMEDEUVIMED entdecken
Crossref

Rare Variants Associated With Pediatric Cancer Treatment–Related Second Malignant Neoplasm Risk

Claire Ducos iD, Brice Fresneau iD, Filippo Rosselli, Giao Vu-Bezin iD, Boris Schwartz, Rodrigue S Allodji iD, Gaelle Marenne iD, Thomas E Ludwig iD, Anne Boland-Augé, Jean-François Deleuze, Helene Blanché iD, Robert Olaso iD und 9 weitere

JCO Precision Oncology · 2025

DOI: 10.1200/po-24-00668 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Claire Ducos und 20 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Epidemiology Team, Center for Research in Epidemiology and Population Health, INSERM Unit 1018, Villejuif, France. Hauptthemen laut MEDLINE: Neoplasms, Second Primary, Neoplasms. Die Arbeit nennt 65 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Survivors of childhood cancers are at risk of second malignant neoplasms (SMNs). Exposure to radiation therapy and different chemotherapy agents are known risk factors for SMN development. However, there remains interindividual variability that could be attributed to genetic variations. Our study aims to identify rare genetic variants associated with SMN risk and assess the influence of treatment on the associated risk of these variants. MATERIALS AND METHODS We conducted a whole-exome sequencing in a nested case-control study within the French Childhood Cancer Survivors Study for 450 survivors including 163 cases and 287 controls. Rare variants in genes within replication, recombination, and repair pathways were selected. Gene-based association tests were conducted and a logistic regression analysis was used to estimate the effect of selected genes on SMN risk, adjusting for relevant clinical variables. Specific analysis restricted to breast and thyroid SMNs were also performed. Stratified analyses on the basis of the radiation doses received by the bone marrow and specific organs were also conducted. RESULTS We have identified several genetic associations: the RNASEL and APOBEC3F genes (odds ratio [OR], 5.43 [95% CI, 1.76 to 20.44]; P = .0055 and OR, 4.8 [95% CI, 1.28 to 22.95]; P = .027, respectively) are associated with the risk of SMN, while the FANCM gene (OR, 4.65 [95% CI, 1.06 to 21.56]; P = .041) is associated with the risk of developing breast SMN. CONCLUSION This study provides new evidence regarding the involvement of genetics in the development of SMN. Additional research is needed to confirm these results and uncover the underlying mechanisms behind these associations. If replicated, these findings will help identify survivors at higher risk of developing SMN, enabling tailored treatment and follow-up strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasms, Second PrimaryNeoplasmsHumansFemaleCase-Control StudiesMaleChildChild, PreschoolAdolescentCancer SurvivorsExome SequencingRisk FactorsInfantGenetic Variation

Autor:innen und Institutionen

  • Radiation Epidemiology Team, Center for Research in Epidemiology and Population Health, INSERM Unit 1018, Villejuif, France.
  • Research Department, Gustave Roussy, Villejuif, France.
  • University Paris Saclay, Villejuif, France.
  • Department of Children and Adolescents Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.
  • CNRS UMR9019, Gustave Roussy Cancer Campus, Université Paris-Saclay, Equipe Labellisée Ligue Nationale Contre le Cancer, Villejuif, France.
  • Univ Brest, Inserm, EFS, UMR 1078, GGB, Brest, France.

ORCID-Profile: Claire Ducos, Brice Fresneau, Giao Vu-Bezin, Rodrigue S Allodji, Gaelle Marenne, Thomas E Ludwig, Helene Blanché, Robert Olaso, Franck Bourdeaut, Ibrahima Diallo, Florent de Vathaire

Zitieren

APA

Ducos, C., Fresneau, B., Rosselli, F., Vu-Bezin, G., Schwartz, B., Allodji, R. S., Marenne, G., Ludwig, T. E., Boland-Augé, A., Deleuze, J. F., Blanché, H., Olaso, R., Nys, J., Winter, S., Bourdeaut, F., El-Fayech, C., Rubino, C., Diallo, I., de Vathaire, F., …, & Haddy, N. (2025). Rare Variants Associated With Pediatric Cancer Treatment–Related Second Malignant Neoplasm Risk. JCO Precision Oncology. https://doi.org/10.1200/po-24-00668

Vancouver

Ducos C, Fresneau B, Rosselli F, Vu-Bezin G, Schwartz B, Allodji RS, et al. Rare Variants Associated With Pediatric Cancer Treatment–Related Second Malignant Neoplasm Risk. JCO Precision Oncology. 2025. doi:10.1200/po-24-00668

BibTeX
@article{Ducos2025,
  author = {Ducos, Claire and Fresneau, Brice and Rosselli, Filippo and Vu-Bezin, Giao and Schwartz, Boris and Allodji, Rodrigue S and Marenne, Gaelle and Ludwig, Thomas E and Boland-Augé, Anne and Deleuze, Jean-François and Blanché, Helene and Olaso, Robert and Nys, Julie and Winter, Sarah and Bourdeaut, Franck and El-Fayech, Chiraz and Rubino, Carole and Diallo, Ibrahima and de Vathaire, Florent and Benhamou, Simone and Haddy, Nadia},
  title = {Rare Variants Associated With Pediatric Cancer Treatment–Related Second Malignant Neoplasm Risk},
  journal = {JCO Precision Oncology},
  year = {2025},
  doi = {10.1200/po-24-00668}
}
Kostenlos starten →